Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

FDA approves capivasertib plus abiraterone for PTEN-deficient metastatic hormone-sensitive prostate cancer

On June 12, 2026, the FDA approved capivasertib with abiraterone and prednisone for PTEN-deficient metastatic androgen-pathway-naive or -sensitive prostate cancer, and approved the VENTANA PTEN (SP218) RxDx Assay, which calls PTEN deficiency when at least 90% of viable malignant cells have no specific cytoplasmic staining; in CAPItello-281 (1,012 patients) median radiographic progression-free survival was 33.2 versus 25.7 months (HR 0.81), and overall survival was immature.

U.S. FDA